EMBO Member
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid | Spain
EMBO 2022
Our group is interested in identifying progression biomarkers and therapeutic agents in melanoma, a highly metastatic disease. We combine histopathological studies in large patient datasets with functional analyses in animal models designed for gene discovery and pharmacological studies in vivo. We have discovered new melanoma drivers and mechanisms of immunoresistance, and have developed anticancer agents with derivatives now in clinical trials.
Keywords: Cancer / melanoma / metastasis / drug development / pharmacological screen
Subject area(s): Differentiation & Death | Genomic & Computational Biology | Immunology | Molecular Medicine | Signal Transduction